Prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes and cardiovascular disease: Results from CATALYST

Summary

Despite advancements in medical treatment, difficult-to-control type 2 diabetes (T2D) remains common in clinical practice and can lead to diabetes-related complications
Hypercortisolism is a known contributing cause of hyperglycemia and is independently linked to higher mortality
In the CATALYST study (NCT05772169), the largest prospective study to date examining the prevalence and characteristics of hypercortisolism in individuals with difficult-to-control T2D, hypercortisolism was found in 24% of participants
Our findings show that the subgroup with cardiovascular disease (CVD) had a higher prevalence of hypercortisolism compared with the group without CVD (33.3% vs 20.9%, P<0.0001)
Given the high prevalence of hypercortisolism, screening may be warranted in individuals with difficult-to-control T2D and CVD
The ongoing CATALYST treatment phase will provide data on therapeutic intervention in individuals with hypercortisolism